• Users Online: 255
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 40  |  Issue : 2  |  Page : 104-106

Fludarabine and bradycardia in recipients of allogeneic stem cell transplant: a case series

Department of Clinical Haematology, Christian Medical College, Ludhiana, Punjab, India

Correspondence Address:
Chepsy C Philip
Department of Clinical Haematology, Christian Medical College, Ludhiana - 141 008, Punjab
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-1067.161297

Rights and Permissions

Fludarabine is being increasingly used both as a chemoimmunotherapeutic agent and in conditioning regimens for stem cell transplant. ECG disturbances with this increasingly used drug have never been reported. This report describes a patient who developed bradycardia following fludarabine administration, prompting an assessment for rhythm irregularities in subsequent patients undergoing stem cell transplant using a fludarabine-based conditioning regimen. In a series of 10 patients who received fludarabine as part of their conditioning, there was a significant effect on QTc interval (mean difference 30.6 ms; P = 0.002) and heart rate (mean difference −18.9 beats/min; P = 0.003). In conclusion, caregivers need to be alert to recognize the potential for unrecognized adverse events even in frequently used drugs. Fludarabine has a potential for rhythm disturbances.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded93    
    Comments [Add]    

Recommend this journal